Recent studies have shown that CRNDE regulates autophagy and ABCG2 expression through the PI3K/Akt/mTOR pathway as a potential biomarker for predicting the treatment response to TMZ and modulating TMZ sensitivity in GBM(Zhao et al., 2021). The gene discussed is MTOR; the disease is glioblastoma.